Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma

  • Mathieu Nessim Toledano
  • P. Desbordes
  • A. Banjar
  • I. Gardin
  • P. Vera
  • P. Ruminy
  • F. Jardin
  • H. Tilly
  • S. Becker
Original Article



This study evaluated the predictive significance of total metabolic tumour volume (TMTV) measured on baseline FDG PET/CT and its value in addition to gene expression profiling using a new method of gene analysis (rapid reverse transcriptase multiplex ligation-dependent probe amplification assay, RT-MLPA) in patients with diffuse large B-cell lymphoma treated with R-CHOP or R-CHOP-like chemotherapies.


The analysis included 114 patients. TMTV was measured using a 41% SUVmax threshold and tumours were classified into GCB or ABC subtypes according to the RT-MLPA assay.


The median follow-up was 40 months. the 5-year progression-free survival (PFS) was 54% and the 5-year overall survival (OS) was 62%. The optimal TMTV cut-off value was 261 cm3. In 59 patients with a high TMTV the 5-year PFS and OS were 37% and 39%, respectively, in comparison with 72% and 83%, respectively, in 55 patients with a low TMTV (p = 0.0002 for PFS, p < 0.0001 for OS). ABC status was significantly associated with a worse prognosis. TMTV combined with molecular data identified three groups with very different outcomes: (1) patients with a low TMTV whatever their phenotype (n = 55), (2) patients with a high TMTV and GCB phenotype (n = 33), and (3) patients with a high TMTV and ABC phenotype (n = 26). In the three groups, 5-year PFS rates were 72%, 51% and 17% (p < 0.0001), and 5-year OS rates were 83%, 55% and 17% (p < 0.0001), respectively. In multivariate analysis, TMTV, ABC/GCB phenotype and International Prognostic Index were independent predictive factors for both PFS and OS (p < 0.05 for both).


This integrated risk model could lead to more accurate selection of patients that would allow better individualization of therapy.


DLBCL FDG PET/CT Metabolic tumour volume ABC/GCB RT-MLPA 



No funding was received for this study.

Compliance with ethical standards

Conflicts of interest


Ethical approval

This study was performed in accordance with the principles of the Declaration of Helsinki and local laws, and the protocol was approved by the Institutional Review Board of Henri Becquerel Centre.

Informed consent

All patients participating in this study provided written informed consent.

Supplementary material

259_2017_3907_Fig4_ESM.gif (32 kb)
Supplementary Fig. 1

Box-and-whisker diagram of TMTV in the whole population. (GIF 31.5 kb)

259_2017_3907_MOESM1_ESM.tif (76 kb)
High resolution image (TIFF 75.9 kb)
259_2017_3907_Fig5_ESM.gif (166 kb)
Supplementary Fig. 2

Kaplan–Meier curves of progression-free survival (PFS) and overall survival (OS) in relation to a baseline total metabolic tumour volume (TMTV) cut-off value of 261 cm3 in patients with unclassifiable phenotype. (GIF 165 kb)

259_2017_3907_MOESM2_ESM.tif (100 kb)
High resolution image (TIFF 100 kb)
259_2017_3907_MOESM3_ESM.png (67 kb)
ESM 1 (PNG 67 kb)


  1. 1.
    Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116:2040–5.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Meignan M, Itti E, Gallamini A, Younes A. FDG PET/CT imaging as a biomarker in lymphoma. Eur J Nucl Med Mol Imaging. 2015;42:623–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44:97–110.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697–703.CrossRefPubMedGoogle Scholar
  10. 10.
    Kim J, Hong J, Kim SG, Hwang KH, Kim M, Ahn HK, et al. Prognostic value of metabolic tumor volume estimated by 18F-FDG positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma of stage II or III disease. Nucl Med Mol Imaging. 2014;48:187–95.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Xie M, Wu K, Liu Y, Jiang Q, Xie Y. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants. Med Oncol. 2015;32:446.CrossRefPubMedGoogle Scholar
  12. 12.
    Xie M, Zhai W, Cheng S, Zhang H, Xie Y, He W. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma. Hematology. 2016;21(2):99–105.PubMedGoogle Scholar
  13. 13.
    Ceriani L, Martelli M, Zinzani PL, Ferreri AJ, Botto B, Stelitano C, et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126:950–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1735–43.CrossRefPubMedGoogle Scholar
  15. 15.
    Cottereau AS, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol. 2016;27(4):719–24.CrossRefPubMedGoogle Scholar
  16. 16.
    Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.CrossRefPubMedGoogle Scholar
  17. 17.
    Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–47.CrossRefPubMedGoogle Scholar
  18. 18.
    Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313–23.CrossRefPubMedGoogle Scholar
  19. 19.
    Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100:9991–6.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Sandoval-Sus JD, Chavez J, Dalia S. A new therapeutic era in GCB and ABC diffuse large B-cell lymphoma molecular subtypes: a cell of origin-driven review. Curr Cancer Drug Targets. 2016;16(4):305–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Bohers E, Mareschal S, Bouzelfen A, Marchand V, Ruminy P, Maingonnat C, et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2014;53(2):144–53.CrossRefPubMedGoogle Scholar
  22. 22.
    Lanic H, Mareschal S, Mechken F, Picquenot JM, Cornic M, Maingonnat C, et al. Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53:34–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Cottereau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, et al. Molecular profile and FDG-PET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B cell lymphoma. Clin Cancer Res. 2016;22(15):3801–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Eldering E, Spek CA, Aberson HL, Grummels A, Derks IA, de Vos AF, et al. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res. 2003;31(23):e153.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mareschal S, Ruminy P, Bagacean C, Marchand V, Cornic M, Jais JP, et al. Accurate classification of germinal center B-cell-like/activated B-cell-like diffuse large B-cell lymphoma using a simple and rapid reverse transcriptase-multiplex ligation-dependent probe amplification assay. J Mol Diagn. 2015;17(3):273–83CrossRefGoogle Scholar
  26. 26.
    Meignan M, Sasanelli M, Casasnovas RO, Luminari S, Fioroni F, Coriani C, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113–22.CrossRefPubMedGoogle Scholar
  27. 27.
    Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour PET imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRefPubMedGoogle Scholar
  28. 28.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefPubMedGoogle Scholar
  29. 29.
    Chalkidou A, O’Doherty MJ, Marsden PK. False discovery rates in PET and CT studies with texture features: a systematic review. PLoS One. 2015;10(5):e0124165.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2008;112:3425–33.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gu K, Weisenburger DD, Fu K, Chan WC, Greiner TC, Aoun P, et al. Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation. Hematol Oncol. 2012;30:143–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29:4079–87.CrossRefPubMedGoogle Scholar
  33. 33.
    Gutiérrez-García G, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, Mate JL, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood. 2011;117(18):4836–43.CrossRefPubMedGoogle Scholar
  34. 34.
    Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk. 2014;14:460–467.e2.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Rayman N, Lam KH, van der Holt B, Koss C, Veldhuizen D, Budel LM, et al. Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials. Clin Lymphoma Myeloma Leuk. 2011;11(1):23–32.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Nuclear Medicine DepartmentHenri Becquerel Cancer Centre and Rouen University HospitalRouenFrance
  2. 2.QuantIF-LITIS (EA 4108-FR CNRS 3638), Faculty of MedicineUniversity of RouenRouenFrance
  3. 3.INSERM U918Centre Henri BecquerelRouenFrance
  4. 4.Hematology DepartmentCentre Henri BecquerelRouenFrance

Personalised recommendations